Immunocore Holdings plc (NASDAQ:IMCR) Q2 2024 Results Conference Call August 8, 2024 8:00 AM ET
Company Participants
Clayton Robertson - Head of Investor Relations
Bahija Jallal - CEO
Brian Di Donato - CFO and Head of Strategy
Ralph Torbay - Head, Commercial
David Berman - Head, R&D
Conference Call Participants
Clayton Robertson - Head of Investor Relations
Bahija Jallal - CEO
Brian Di Donato - CFO and Head of Strategy
Ralph Torbay - Head, Commercial
David Berman - Head, R&D
Mohammed Dar - CMO
Michael Yee - Jefferies
Elias Lenard - JPMorgan
Tyler Van - TD Cowen
Eric Schmidt - Cantor Fitzgerald
Michael Schmidt - Guggenheim
Jack Allen - Baird
Justin Zelin - BTIG
Jonathan Chang - Leerink Securities
Ahu Demir - Ladenburg Thalmann
Avantika Joshi - Mizuho
Naureen Quibria - Capital One Securities
Rajan Sharma - Goldman Sachs
Ethan Markowski - Needham & Company
Operator
Welcome to the Immunocore Conference Call and Webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded.
I would now like to turn the call over to Clayton Robertson, Head of Investor Relations. Thank you. You may begin.
Clayton Robertson
Good morning, and good afternoon. Thank you for joining us on our Q2 and first half 2024 earnings call today. During today's call, we will make some forward-looking statements, which are qualified by our safe harbor provision under the Private Securities Litigation Reform Act of 1995. Please note that actual results can vary materially from those indicated by these forward-looking statements, including those discussed in our filings with the SEC.
On today's call, I'm joined by Bahija Jallal, CEO of Immunocore; and Brian Di Donato, CFO and Head of Strategy, who will share a strategy update. Ralph Torbay, Head of Commercial, will review our first half KIMMTRAK sales and additional growth opportunities for KIMMTRAK. David Berman, Immunocore's Head of R&D, will provide some pipeline updates, including near-term readouts in oncology and infectious diseases.
Brian will also provide highlights on our financial results reported this morning. Bahija?
Bahija Jallal
Thank you, Clay. As you may be able to hear, I'm losing my voice, and I have pharyngitis. So to be able to answer your questions at the end, I will ask Brian to pinch-hit for me.
Brian, please?
Brian Di Donato
Thank you, Bahija. We hope you feel better. We are pleased to share with you an update on Immunocore through the first half of 2024. We've achieved excellent commercial results while advancing our T cell engager platform in three therapeutic areas. We appreciate your continued support in advancing our mission of delivering innovative and life-changing medicines to patients.